Browse > Article
http://dx.doi.org/10.7742/jksr.2017.11.7.597

A Study on the Effective Half-life after the High Dose Radioactive Iodine (131I) Therapy for Thyroid Cancer Patients  

Kim, Seongcheol (Department of Radiological Science, Daegu Catholic University)
Gwon, DaYeong (Department of Radiological Science, Daegu Catholic University)
Kim, Yongmin (Department of Radiological Science, Daegu Catholic University)
Publication Information
Journal of the Korean Society of Radiology / v.11, no.7, 2017 , pp. 597-603 More about this Journal
Abstract
High-dose $^{131}I$ therapy has been generally carried out to remove remaining thyroid tissue or to cure metastasize lesion of patients who received full thyroidectomy due to differentiated thyroid cancers. In case high-dose $^{131}I$ therapy is carried out for a patient, the patient should be hospitalized being isolated for a certain period in order to restrict the amount of exposure to radiation of people at large from the patient within the limit of a level of radiation. Effective half-life is an important value to calculate how family members are exposed to radiation from a patient or to decide the period of isolation of the patient from the family members. Therefore, in this study we calculated the effective decay constant, effective half-life and period of isolation of high-dose $^{131}I$ therapy patient using NM670 SPECT/CT. As a result of carrying out this study, the effective half-life of high-dose $^{131}I$ therapy patients was derived and the time to reach the discharge level of 1.2 GBq was confirmed. When they were compared with each other in each of curative doses, the effective half-life did not have significant difference, but the time when the level of radiation remaining in the interior of the body to reach the criteria of isolation and discharge showed significant difference and it could be confirmed that the higher the curative dose the longer the period of isolation becomes. When the effective half-lives in each type of preparation were compared with each other, they did not show significant difference. However, When the times to reach the level of radiation that is the criteria of isolation and discharge in each type of preparations, they showed significant difference. The cause of the shortening of the isolation period for rhTSH patients group is decided to be low curative dose. Accordingly, if the current national health insurance (the insurance is applied to using of rhTSH in 3.7 GBq or lower) is maintained, while discerning them in each of types of preparation, we would be able to discharge patients at the time earlier than the current period of isolation (2 nights and 3 days).
Keywords
$^{131}I$; Radioactive iodine therapy; Effective half-life; rhTSH;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 V. Angela, C. Traino, B. Giuseppeb, G. Marianob, L. Patriziab, C. Chiarac, D. Maria Vittoriad, F. Giorgiod, L. Mauroa, M. Giulianob, F. Marcoe "Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal." Nuclear Medicine Communications, Vol. 28, No. 3, pp. 215-23, 2007.   DOI
2 B. Aschebrook-Kilfoy, M. H. Ward, M. M. Sabra, S. S. Devesa. "Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006." Vol. 21, No. 2, pp. 125-34, 2011.   DOI
3 United States Nuclear Regulatory Commission Office of Federal and State Material and Environmental Management Programs 2009 Washington, DC: 20555-0001. NRC Information Notice 2003-22, Supplement 2009.
4 Nuclear Safety Commission No. 19 Regulations on Technical Standards such as Radiation Safety Management. Nuclear Safety Commission Notification No. 2015-5 Technical Standards on Radiation Safety Management in the Medical Sector
5 K. H. Yi, E. K. Lee, H. C. Kang, Y. W. Koh, S. W. Kim, I. J. Kim, D. G. Na, K. H. Nam, S. Y. Park, J. W. Park, S. K. Bae, S. K. Baek, J. H. Baek, B. J. Lee, K. W. Chung, Y. S. Jung, G. J. Cheon, W. B. Kim, J. H. Chung, Y. S. Rho, "2016 Revised Korean Thyroid Association Management Guidelines for Patient with Thyroid Nodules and Thyroid Cancer." Int J Thyroidol, Vol. 9, No. 2, pp. 59-126, 2016.   DOI
6 S. G. Park. "Effective Half-life of I-131 in Patients with Differentiated Thyroid Cancer Treated by Radioactive I-131." The Korea Society of Nuclear Medicine, Vol. 42, No. 6, pp. 464-468, 2008.
7 S. G. Park. "Suggestion of A Practical Simple Calculation Method for Safe Transportation Time after Radioactive Iodine Treatment in Patients with Thyroid Cancer." Journal of the Korea Academia - Industrial cooperaion Society,Vol. 16, No. 6, pp. 3919-25, 2015.   DOI
8 D. L. North, D. R. Shearer, J. V. Hennessey, G. L. Donovan. "Effective half-life of 131I in thyroid cancer patients." The radiation safety journal Health Physics Vol. 81, No. 3, pp. 325-9, 2001.
9 C.D. Venencia, A.G Germanier, S.R. Bustos, A.A. Giovannini, E.P. Wyse."Hospital discharge of patient with thyroid carcinoma treated with 131I." The Journal of Nuclear Medicine, Vol. 43, No. 1, pp. 61-5, 2002.
10 U. Mallick, C. Harmer, B. J. Wadsley, S. Clarke, L. Moss, A. Nicol, P. M. Clark, K. Farnell, R. McCready, J. Smellie, J. A. Franklyn, S. John, C. M. Nutti ng, K. Newbold, C. Lemon, G. Gerrard, A. Abdel-Hamid, J. Hardman, E. Macias, T. Roques, S. Whitaker, R. Vijayan, P. Alvarez, S. Beare, S. Forsyth, L. Kadalayil, A. Hackshaw, "Ablation with low-dose radioio dine and thyrotropin alfa in thyroid cancer." The new england journal of medicine, Vol. 366, No. 18, pp. 1674-85, 2012.   DOI
11 H. Remy, I. Borget, S. Leboulleux, N. Guilabert, F. Lavielle, J. Garsi, C. Bournaud, S. Gupta, M. Schlumberger, and M. Ricard. "131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients Preparing Patients for Radioiodine Treatment: Increasing Thyroid Cell Uptake and Accelerating the Excretion of Unbound Radioiodine." The Journal of Nuclear Medicine, Vol. 49, No. 9, pp. 1445-50, 2008.   DOI
12 M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie, C. Schvartz, P. Vera, O. Morel, D. Benisvy C. Bournaud, F. Bonichon, C. Dejax, M. Toubert, S. Leboulleux, M. Ricard, E. Benhamou, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer." The new england journal of medicine, Vol. 366, No. 18, pp. 1663-73, 2012.   DOI
13 J. D. Lee, M. J. Yun, K. H. Nam, Y. W. Chung, E. Y. Soh, C. S. Park. "Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma." Thyroid, Vol. 20, No. 2, pp. 173-9, 2010.   DOI
14 Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study." J Clin Endocrinol Metab, Vol. 91, No. 3, pp. 926-32, 2006.   DOI
15 M. Matovic, Edited by Dr. Thomas J. Fahey, "Preparing Patients for Radioiodine Treatment: Increasing Thyroid Cell Uptake and Accelerating the Excretion of Unbound Radioiodine." Updates in the Understanding and Management of Thyroid Cancer (InTech), pp. 306, 2012.